Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | APR-246 with azacitidine for p53 mutated MDS and AML

Thomas Cluzeau • 12 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes APR-246 Azacitidine

Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the use of APR-246, a PRIMA-1 analog targeting p53 in combination with azacitidine for TP53 mutated myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Thomas Cluzeau

1:40
Highlights in LR-MDS at the ASH 2023 meeting
Thomas Cluzeau • 9 Dec 2023
1:55
Long-term real-world experience of CPX-351 in patients with t-AML and MRC-AML
Thomas Cluzeau • 9 Dec 2023
2:17
VENTOGRAFT trial: AZA, VEN, and DLI in patients with MDS and AML who have relapsed following alloSCT
Thomas Cluzeau • 10 Dec 2023
Novel targets, combinations & treatments
Eunice Wang et al. • 4 Sep 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals